Halozyme Therapeutics Inc., of San Diego, and Ventana Medical Systems Inc., a member of the Roche Group, of Basel, Switzerland, inked a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's investigational new drug, PEGPH20.